RARE DISEASERESEARCH ATLAS
Open navigation menu

ORPHA:1276

Brachydactyly-arterial hypertension syndrome

low confidenceDisorder

Also known as: Bilginturan brachydactyly · Bilginturan syndrome · Brachydactyly type E, with short stature and hypertension

Publications

2,896

Trials

0

Interventional, condition-specific

Researchers

535

Distinct authors in sample

Gene link

PDE3A

Strong

Readiness

3/6

Stages with a signal

Clinical definition (Orphanet)

A rare genetic brachydactyly syndrome characterized by the association of brachydactyly type E with hypertension (due to vascular or neurovascular anomalies) as well as the additional features of short stature and low birth weight (compared to non-affected family members), stocky build and a round face. The onset of hypertension is often in childhood.

How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (1)

brachydactyly type E, with short stature and hypertension

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

3/6 stages with a signal

No matched interventional trial; the gene is known and literature exists — preclinical or natural-history work may still be the practical next step.

  1. Gene identifiedPresent

    Strong — PDE3A

  2. LiteraturePresent

    2,896 matched papers (1,940 in last 10 years) Source

  3. Phenotype characterisedPresent

    11 HPO annotations (e.g. Brachydactyly; Short phalanx of finger; Short metacarpal) Source

  4. Animal modelNot found

    No Alliance genotype “model of” associations via Monarch for these Mondo IDs

  5. Orphan designationNot found

    No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source

  6. Interventional trialNot found

    No matched interventional trial under our ClinicalTrials.gov rules

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Yes — we know a specific gene responsible (PDE3A).

GenCC classification: Strong.

Phenotypes (Monarch / HPO)

11

Associated phenotypes · MONDO:0007211

  • Brachydactyly
  • Short phalanx of finger
  • Short metacarpal
  • Hypertension
  • Short stature

Showing 5 of 11 — open Monarch for the full list.

Animal models (Monarch / Alliance)

None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.

Monarch fetch 2026-07-29

Therapies

Designations, candidates, and chemicals

FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.

Orphan designation (FDA · EMA)

No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.

Open Targets candidates

No drugs or clinical candidates returned for this Mondo ID on Open Targets.

CTD chemicals (MyDisease.info)

3 associated chemicals · 13 pathways. Therapeutic evidence is listed first when present — not a treatment recommendation.

  • Amlodipine · therapeutic
  • Enalapril · therapeutic
  • Metoprolol · therapeutic

Pathways: Purine metabolism; cGMP-PKG signaling pathway; cAMP signaling pathway; Renin secretion; Morphine addiction; Hemostasis; Signal Transduction; Signaling by GPCR

MyDisease.info · MONDO:0007211

Literature

Is anyone studying this?

2,896

2,896 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.

2,896 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).

1,940 in the last 10 years · low confidence

Phrase hits: 59 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

535

Distinct author names in 59 sampled papers — named people below.

Who's working on it?

No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.

  1. 01
    Klussmann E4 papers · 2023

    Max Delbrück Center for Molecular Medicine Berlin (MDC), Berlin 13125, Germany. enno.klussmann@mdc-berlin.de.

    Papers in Europe PMC
  2. 02
    Liu Z4 papers · 2026

    Shiyan Key Laboratory of Virology, Hubei University of Medicine, Shiyan, China.

    Papers in Europe PMC
  3. 03
    Aydin A3 papers · 2022

    1] Experimental and Clinical Research Center (ECRC), a joint cooperation between the Charité Medical Faculty and the Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany. [2] Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany.

    Papers in Europe PMC
  4. 04
    Bähring S3 papers · 2022

    1] Experimental and Clinical Research Center (ECRC), a joint cooperation between the Charité Medical Faculty and the Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany. [2] Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany.

    Papers in Europe PMC
  5. 05
    Ercu M3 papers · 2023

    Max Delbrück Center for Molecular Medicine Berlin (MDC), Berlin 13125, Germany. maria.ercu@mdc-berlin.de.

    Papers in Europe PMC
  6. 06
    Luft FC3 papers · 2015

    1] Experimental and Clinical Research Center (ECRC), a joint cooperation between the Charité Medical Faculty and the Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany. [2] Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany. [3] Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.

    Papers in Europe PMC
  7. 07
    Maass PG3 papers · 2022

    Department of Genetics, Nephrology, Hypertension, and Vascular Injury, Max-Delbrück Center for Molecular Medicine (MDC), Robert-Rössle Strasse 10, 13125 Berlin, Germany.

    Papers in Europe PMC
  8. 08
    Toka HR3 papers · 2015

    Department of Genetics, Howard Hughes Medical Institute, Yale University School of Medicine, New Haven, Connecticut, USA.

    Papers in Europe PMC
  9. 09
    Alyabyeva PV2 papers · 2023

    Shared Core Facilities Molecular and Cell Technologies, V.F. Voino-Yasenetsky Krasnoyarsk State Medical University, 660022 Krasnoyarsk, Russia.

    Papers in Europe PMC
  10. 10
    Chitayat D2 papers · 2015

    Hospital for Sick Children, Toronto, Ontario, Canada.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

0

interventional trials for this specific condition

No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).

Data as of 11 September 2026 · last trial check 11 September 2026

No matched interventional trials. This is true for 77.2% of diseases in the trials denominator (5501 of 7126). Here are the researchers publishing on it.

low confidence · 38.6th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.

Broader category brachydactyly also has no matched interventional trial. See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.

Broader category: brachydactyly

0

Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.

Parent-category matching found a broader label but no interventional trials under it. How we count trials.

Other registries (secondary)

Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.

raw 0 · after dedupe 0 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 0 · dropped 0 · fetched 2026-07-29

Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri

No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).

Where to find support

Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.

Orphanet entry for Brachydactyly-arterial hypertension syndrome — check Associations / patient organisations on that page.

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

("Brachydactyly-arterial hypertension syndrome" OR "Bilginturan brachydactyly" OR "Bilginturan syndrome" OR "Brachydactyly type E, with short stature and hypertension") OR ("PDE3A" OR "PDE3A syndrome" OR "PDE3A-related")

Run this search on Europe PMC

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Brachydactyly-arterial hypertension syndrome" OR "Bilginturan brachydactyly" OR "Bilginturan syndrome" OR "Brachydactyly type E, with short stature and hypertension"

Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.

Parent-category trials query:

"brachydactyly"

Query health: ok — strategies attempted: phrase; with hits: phrase

Run this search on ClinicalTrials.gov

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • No synonyms dropped by stoplist
  • No label/synonym collisions with other diseases in this corpus
  • Publication count (2896) is implausibly high for prevalence class "<1 / 1 000 000" — treat as possible over-matching, not a measure of research intensity

Ingested 2026-07-26T16:54:23.928Z